Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting KRAS in pancreatic cancer
Sandra Stickler, Barbara H. Rath, Gerhard Hamilton
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2024) Vol. 32, Iss. 5, pp. 799-805
Open Access | Times Cited: 18

Showing 18 citing articles:

Consensus, debate, and prospective on pancreatic cancer treatments
Junke Wang, Jie Yang, Amol Narang, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 11
A stumbling block in pancreatic cancer treatment: drug resistance signaling networks
Jinming Liu, Biao Zhang, Bingqian Huang, et al.
Frontiers in Cell and Developmental Biology (2025) Vol. 12
Open Access | Times Cited: 1
Dynamic Coupling of MAPK Signaling to the Guanine Nucleotide Exchange Factor GEF-H1
Kévin Leguay, Oliver A. Kent
OncoTargets and Therapy (2025) Vol. Volume 18, pp. 147-159
Open Access | Times Cited: 1
Current Strategies and Future Dimensions in the Development of KRAS Inhibitors for Targeted Anticancer Therapy
Laura D'Alessio‐Sands, Joshua Gaynier, Victoria Michel‐Milian, et al.
Drug Development Research (2025) Vol. 86, Iss. 1
Closed Access
Pathway-specific genomic alterations in pancreatic cancer across diverse cohorts
Cecilia Monge, Brigette Waldrup, Francisco J. Carranza-Chávez, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
The Association of Aquaporins with MAPK Signaling Pathway Unveils Potential Prognostic Biomarkers for Pancreatic Cancer: A Transcriptomics Approach
Inês V. da Silva, Paula A. Lopes, Elisabete Fonseca, et al.
Biomolecules (2025) Vol. 15, Iss. 4, pp. 488-488
Open Access
Contributions of Low-frequency-mutated Genes in Pancreatic Tumorigenesis and Their Implications in Precision Cancer Therapy
Shih‐Han Hsu, Tzu-Lei Kuo, Ming‐Chuan Hsu, et al.
Journal of Cancer Research and Practice (2025) Vol. 12, Iss. 1, pp. 1-5
Open Access
Synergistic anti-tumor activity, reduced pERK, and immuno-stimulatory cytokine profiles with 5-FU or ONC212 plus KRAS G12D inhibitor MRTX1133 in CRC and pancreatic cancer cells independent of G12D mutation
Vida Tajiknia, Maximilian Pinho-Schwermann, Praveen Srinivasan, et al.
American Journal of Cancer Research (2024) Vol. 14, Iss. 9, pp. 4523-4536
Closed Access | Times Cited: 3
High-throughput kinetics in drug discovery
Maria Filipa Pinto, Julija Sirina, Nicholas D. Holliday, et al.
SLAS DISCOVERY (2024) Vol. 29, Iss. 5, pp. 100170-100170
Open Access | Times Cited: 1
Advancements in Targeted Therapeutics: Integrating Metabolic Modulation, Immune Engineering, and Biologic Formulation Technologies
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 9, pp. 1430-1432
Open Access
Bringing Hope to Improve Treatment in Pancreatic Ductal Adenocarcinoma—A New Tool for Molecular Profiling of KRAS Mutations in Tumor and Plasma Samples
Ana Catarina Bravo, B Morão, André Luz, et al.
Cancers (2024) Vol. 16, Iss. 20, pp. 3544-3544
Open Access
The impact of nutrition on post-duodenopancreatectomy recovery in a patient with cephalic and body-tail pancreatic neoplasm – case report
Sorina-Mădălina Boariu, Ana‐Maria Scutariu, Valentina Anton, et al.
˜The œRomanian Journal of Nutrition. (2024) Vol. 3, Iss. 3, pp. 4-4
Closed Access
Emerging horizons on molecular and circulating biomarkers in pancreatic adenocarcinoma
Marta Moretti, Antonella Farina, Antonio Angeloni, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
KRas plays a negative role in regulating IDO1 expression
Xiandong Peng, Eun‐Ji Lee, Ji‐An Liang, et al.
Translational Oncology (2024) Vol. 51, pp. 102167-102167
Closed Access
Combinations of RAS pathway inhibitors with targeted agents are active in spheroids of patient-derived cells with oncogenic KRAS variants from multiple cancer types
Zahra Davoudi, Thomas S. Dexheimer, Nathan P. Coussens, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Suite of Biochemical and Cell-Based Assays for the Characterization of Kirsten Rat Sarcoma (KRAS) Inhibitors and Degraders
Medhanie Kidane, Rene M. Hoffman, Jennifer K. Wolfe-Demarco, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 12, pp. 3921-3934
Open Access
Molecular pathway analysis using comparative genomic and epigenomic data
Ye Wang, Marianna Zolotovskaia, Anton Buzdin
Elsevier eBooks (2024), pp. 203-231
Closed Access
A Novel circ_0075829/miR‐326/GOT1 ceRNA Crosstalk Regulates the Malignant Phenotypes and Drug Sensitivity of Gemcitabine‐Resistant Pancreatic Cancer Cells
Yongjia Xiang, Ronghua Zhou, Yi Yang, et al.
Journal of Biochemical and Molecular Toxicology (2024) Vol. 39, Iss. 1
Closed Access
Page 1

Scroll to top